CARTER-WALLACE
ANNUAL REPORT FOR THE YEAR ENDED MARCH 31 2001
EXECUTIVE OFFICES
1345 Avenue of the Americas, New York, N.Y. 10105
212-339-5000
RESEARCH LABORATORIES
Cranbury, New Jersey
MANUFACTURING PLANTS
Cranbury, New Jersey
Colonial Heights, Virginia
Decatur, Illinois
Winsted, Connecticut
Montreal, Canada
Folkestone, England
Milan, Italy
Mexico City, Mexico
New Plymouth, New Zealand
Barcelona, Spain
TRANSFER AND DISBURSING AGENT
The Bank of New York
101 Barclay Street
New York, N.Y. 10286
800-524-4458
REGISTRAR OF STOCK
The Bank of New York
101 Barclay Street
New York, N.Y. 10286
SHAREHOLDER RELATIONS
RFBinder Partners, Inc.
800-984-1777
CARTER-WALLACE, INC.
ANNUAL REPORT
For the year ended March 31, 2001
FINANCIAL HIGHLIGHTS 2001 2000
Net sales from continuing operations $222,727,000 $207,866,000
Earnings (loss) from continuing operations (334,000) 1,359,000
Earnings from discontinued operations 49,556,000 41,973,000
Net earnings $ 49,222,000 $ 43,332,000
Earnings (loss) per share--basic:
From continuing operations $ (.01) $ .03
From discontinued operations 1.10 .93
Earnings per share--basic $ 1.09 $ .96
Earnings (loss) per share--diluted:
From continuing operations $ (.01) $ .03
From discontinued operations 1.05 .91
Earnings per share--diluted $ 1.04 $ .94
Dividends $ 14,497,000 $ 10,809,000
Dividends per share $ .32 $ .24
Average shares outstanding 45,311,000 45,019,000
Number of stockholders of record
Common 1,741 1,913
Class B common 1,065 1,142
[LOGO]
The Company markets
toiletries, pharmaceuticals,
diagnostic specialties,
proprietary drugs and pet products
CONTENTS
Report to Stockholders 2
Summary of Selected Financial Data 7
Management's Discussion and
Analysis of Results of Operations
and Financial Condition 8
Description of Business 11
Consolidated Balance Sheets 12
Consolidated Statements of Earnings, Retained
Earnings and Comprehensive Earnings 14
Consolidated Statements of Cash Flows 15
Notes to Consolidated Financial Statements 16
Independent Auditors' Report 31
Directors and Officers 32
REPORT TO STOCKHOLDERS
PENDING SALE OF THE COMPANY
In May 2001 the Company announced it had entered into agreements for the sale of
the Company in a two-step transaction in which stockholders will receive $20.30
per share, subject to certain closing adjustments. This transaction is pending
at this time and is subject to approval by stockholders and other conditions.
Full details will be included in a proxy statement regarding this transaction
which will be sent to all stockholders.
In this two-step transaction, the consumer business, consisting of the Carter,
Lambert Kay and International Divisions will be sold by the Company immediately
prior to the merger of the remainder of the Company. Accordingly, the consumer
business is included as a discontinued operation for all periods presented in
the March 31, 2001 financial statements.
SALES AND EARNINGS
Net sales from continuing operations (the health care business) were
$222,727,000, a 7% increase over the sales of $207,866,000 in the prior year.
Net sales from discontinued operations (the consumer products business)
increased by 3.5% to $558,665,000 from the prior year's $539,802,000. Lower
foreign exchange rates in international markets reduced consumer products sales
by $22,000,000 compared to the prior year.
Net earnings for the Company increased by 14% to $49,222,000, or $1.09 per basic
share, compared with $43,332,000 or $.96 per basic share in the prior year.
Earnings from discontinued operations related to the consumer business were
$49,556,000 in the current year compared with $41,973,000 in the prior year. The
results for continuing operations related to the health care business, which
includes a substantial portion of corporate overhead, were a net loss of
$334,000 in the current year compared with net earnings of $1,359,000 a year
earlier.
DIVIDENDS
Dividends of $.32 per share were paid in the fiscal year ended March 31, 2001
compared to $.24 per share in the prior year. The Company has paid dividends for
118 consecutive years.
CARTER PRODUCTS DIVISION
The Division achieved another record in sales revenues for the year through
innovative new product introductions and the further strengthening of several
core franchises. This performance was attained even as the retail industry
continued to consolidate. The Division's key brand segments remained prominent
in the market and several lead their category.
Factory shipments of Trojan brand condoms reached another record high. Combined
market share for all the Division's condom brands continued to rise to over 68%
of total condom category sales this year. Innovative line extensions, leadership
advertising, effective promotion and comprehensive educational programs continue
to improve the brand's leading position in this market. Trojan Extended Pleasure
condoms and Magnum XL condoms were introduced in February 2001.
The Arrid and Lady's Choice lines of anti-perspirants and deodorants continue to
be competitive while category activity intensifies. The Arrid brand successfully
introduced new fragrances for the solid and aerosol segments. Lady's Choice
introduced a new ultra clear solid formula. Arrid continued its successful
advertising campaign, focusing on the powerful protection of Arrid in stressful
situations.
2
The Nair line of hair removal products continues to be the number one brand in
this category and has increased sales volume in the depilatory and wax segments.
Nair Body Cream and Nair Apple Licious lotion were successfully introduced in
the latter part of the year, further expanding the presence of Nair in the fast
growing hair removal category.
Pearl Drops continues to be competitive in the specialty tooth whitening
category. This segment faces pressure from mainstream brands that have
introduced whitening line extensions.
The Division continues to be one of the leading marketers of at-home pregnancy
and ovulation test kits. Sales of the First Response pregnancy test grew
significantly over the previous year based on a new four day claim. First
Response allows you to test four days earlier than any other at-home pregnancy
test. Answer pregnancy and ovulation test kits performed well, showing increased
sales year to year.
WALLACE LABORATORIES DIVISION
The Wallace Laboratories Division posted strong sales performance from the
continued growth of Astelin Nasal Spray as well as the Ryna and Tussi families
of prescription cough/cold products.
Astelin Nasal Spray is the only prescription antihistamine nasal spray on the
market. In June 1999, a filing was made to the Food and Drug Administration
(FDA) for the Astelin pediatric indication, which was approved in May 2000. The
new indication lowered the age for which Astelin is indicated from twelve years
and above, to five years and above for seasonal allergic rhinitis.
Two studies evaluating Astelin Nasal Spray in patients with vasomotor
(perennial, nonallergic) rhinitis were completed during the prior fiscal year.
Both studies demonstrated that Astelin was effective across all the measured
symptoms of vasomotor rhinitis, and a filing was made to the FDA in November
1999 for this indication. In September 2000, Astelin received approval, making
it the only antihistamine on the market that is indicated for both seasonal
allergic and vasomotor nonallergic rhinitis.
Recently published data report that over 57 percent of "rhinitis" patients have
nonallergic rhinitis, either alone or in conjunction with allergic rhinitis.
This new indication, therefore, represents an opportunity for Astelin and makes
it distinct from the oral antihistamines that are only indicated for allergic
rhinitis. Astelin sales growth accelerated immediately following the November
2000 introduction of this new indication, and was sustained throughout the
balance of the fiscal year.
Astelin will be the primary promoted product throughout the year, as vasomotor
nonallergic rhinitis is a non-seasonal indication.
Astelin Nasal Spray is marketed under a joint venture agreement with ASTA Medica
AG. Under this agreement, Carter-Wallace, through the Wallace Laboratories
Division, is responsible for all manufacturing, selling, marketing and
administrative services for Astelin and is compensated by the joint company for
these activities.
The Division's promoted cough/cold products, Rynatan Tablets, Ryna-12
Suspension, and Tussi-12 Tablets and Suspension continue to respond well to
promotion. Sales of this product line benefited from recent reformulations and
line extensions and posted strong growth. Additional reformulations and line
extensions are planned.
While major promotional emphasis was placed on Astelin Nasal Spray and the
cough/cold products, the Soma family of products also received promotional
support targeted to appropriate physicians throughout the year.
In addition to the line extensions that the Division continues to explore, new
pharmaceutical products and licensing/acquisition opportunities that would
broaden or complement existing product lines, as well as co-promotion agreements
are being pursued.
3
WAMPOLE LABORATORIES DIVISION
A strong sales year led to the Division achieving record earnings. Impressive
sales increases were recorded in both of the Division's emphasis areas: rapid
tests for the point of care market and automated tests systems for the larger
hospital and reference laboratory.
In the point of care area, particularly strong growth was recorded for rapid
tests to aid in the determination of pregnancy as well as for tests to aid in
the diagnosis of Lyme disease, chlamydia and C. difficile infections. The
introduction of related products for the detection of antibodies to H. pylori,
an infectious bacterium associated with stomach ulcers, and for the detection of
group A streptococcus in throat cultures, is expected to help continue this
growth.
For larger laboratories, the Wampole line of automated enzyme immunoassay (EIA)
products continued to show excellent growth. In the infectious disease market,
sales of a variety of viral serology products moved up significantly as a number
of large national accounts converted to the Wampole line. At the same time, EIA
tests for a range of autoimmune diseases and for Lp(a), a cardiovascular risk
marker, also showed impressive growth. The Division intends to broaden its
cardiovascular line with additional products to be launched in the coming year.
The Wampole strategy of partnering with Allegiance Healthcare, one of the
largest distributors of healthcare products in the country, continues to pay
dividends. The partnership provides an effective strategy for Wampole to
penetrate many of the managed care groups with which Allegiance has preferred
vendor status.
LAMBERT KAY DIVISION
Lambert Kay offers a broad range of products used primarily for the care of dogs
and cats and treatment of the environment in which they live. The Division's
products are sold in independent and chain pet stores, pet product catalogs and
Internet sites and in several mass market and grocery chains.
The Division's products fall into seven major categories: grooming aids,
grooming tools, nutritional supplements, medical products, toys, training and
waste management aids, and chain collars and leads. Many Lambert Kay brands,
such as Fresh'n Clean grooming aids, Evict liquid wormers for dogs, Boundary
repellents, and Tuff on Tangles slicker brushes are well known leaders in their
categories.
Lambert Kay achieved sales growth this year due in a large part to increased
sales to pet chain and mass market stores. The successful introduction of four
new grooming aids and tools were also contributors to this growth. New Fresh'n
Clean cologne drops were introduced in three popular fragrances. The Division
also introduced Fresh'n Clean pet shampoo with a popular baby powder scent,
oatmeal and baking soda shampoo for skin conditioning and pet odor control, and
Ever Gentle massage and grooming brushes made with unique rubber "nubs" which
remove dead hair from the coat and stimulate the production of natural
conditioning oils.
INTERNATIONAL DIVISION
The International Division had a successful year achieving record earnings
despite significant foreign exchange translation pressures which reduced sales
by $22 million. Sales as measured in local currency were strong with foreign
subsidiary operations showing overall growth. The sales gains were achieved
through selective price increases as well as unit volume advances in a number of
operations including Canada, France, Mexico and Spain.
Consumer products displayed sales gains in a number of product segments and
geographic areas.
Our depilatory line, bolstered by a number of line extensions, performed
extremely well. Nair showed substantial sales gains in Canada, Mexico,
Australia, England and France while our Taky brand in Spain
4
achieved notable sales growth and an expanded market share.
The face and skin care segment continued to advance. In France, record sales
were achieved for Lineance, a line of anti-cellulite skin care products. Gains
were also achieved for Barbara Gould, a leading line of make-up removers,
cleansers and other facial skin care products in France, largely due to the
introduction of new products. Eudermin, a range of skin care creams in Spain
also demonstrated growth and a higher market share.
A strong presence was maintained in the highly competitive oral care segment.
Pearl Drops advanced significantly in Italy and continued to be a leading brand
in England, Germany and several other European countries. Email Diamant showed
strong growth in France. Nacar Blanco advanced significantly in Mexico following
a successful relaunch of the brand with new products and packaging.
The Trojan brand of condoms showed strong growth in Canada as a result of line
extensions and effective advertising and promotion and achieved a leading 46%
market share. The Trojan line was re-staged with new packaging in Mexico during
the year and achieved sales gains with expanded distribution.
The Division's line of over-the-counter health care products maintained strong
positions in a number of foreign markets. In Canada, Gravol anti-nauseant
advanced, maintaining its dominant market position. Sales gains were also
achieved in Canada for Ovol anti-flatulent and Bentasil throat lozenges. Our
brands of topical analgesic products, Antiphlogistine Rub A-535 in Canada and
Dencorub in Australia, maintained their leading positions and continued to
perform well. In France, Sterimar continued to maintain a leading share while
exports of Sterimar from France were expanded substantially. OTC health care
sales in Italy were very strong led by Cerulisina, a preparation to remove ear
wax. Notable growth was also achieved in Mexico for the Pangavit line of vitamin
supplements. The Division has maintained a strong presence for its home
pregnancy and ovulation products in Australia, Canada, Italy, England and
Mexico, despite severe price competition and an increasing number of private
label brands.
Professional diagnostic sales showed growth in segments of our ELISA product
line. Expanded sales in the Middle East and in South America complemented strong
sales in Europe and Canada for both infectious disease and autoimmune products.
Our subsidiary in Italy introduced new and improved performance tests for
syphilis, herpes and cytomegalovirus to expand the menu of products that can be
performed on their Gralis automated instrument. Significant growth was also seen
in sales of autoimmunity and cardiovascular products. In France, the
introduction of a new line of chemistry reagents helped expand the product line.
Sales for parasitology products continued to be strong in France.
RESEARCH & DEVELOPMENT
Research at independent facilities determined that taurolidine induced cell
death in numerous human cancer cells in vitro. These developments prompted the
Company to initiate an R&D program directed at multiple cancer cell lines to
determine if taurolidine has clinically important antineoplastic activity. An
Investigational New Drug Application (IND) was filed with and accepted by the
FDA. Clinical trials in patients with brain, ovarian and mesothelioma cancer are
in progress.
Two multicenter clinical studies showed that Astelin Nasal Spray is effective
for treating vasomotor (nonallergic) rhinitis. A Supplemental New Drug
Application was approved by the FDA for use in vasomotor rhinitis in September,
2000. Astelin Nasal Spray is now indicated for both allergic and nonallergic
vasomotor rhinitis in adults and for use in children five years of age and older
for seasonal allergic rhinitis. The Astelin tablet NDA for allergic rhinitis is
pending at the FDA. The Company has not decided whether to seek final approval
for this NDA.
5
The Company licensed from the University of Virginia Patent Foundation a new
chemical entity, fluorofelbamate. In preclinical studies, this compound appears
to have six to ten times greater antiseizure effectiveness than felbamate and
may not produce a toxic metabolite isolated from felbamate metabolism believed
to be the underlying cause of felbamate toxicity.
FACILITIES
During the year our Mexican administrative and manufacturing operations were
relocated to a single renovated facility in Mexico City. The sale of our former
pharmaceutical plant in Mexico was completed in the first quarter of the new
fiscal year.
PEOPLE
Henry H. Hoyt, Jr. retired as Chairman of the Board of Directors and Chief
Executive Officer after more than 50 years with the Company. Mr. Hoyt was
appointed Chairman Emeritus and continues to serve on the Board of Directors.
Throughout his long career with Carter-Wallace, Mr. Hoyt provided the guidance
and vision that led to a focus on market leadership and resulted in sustained
long term growth of the Company's sales and profitability.
Ralph Levine, formerly President and Chief Operating Officer, succeeded Mr. Hoyt
as Chairman of the Board and Chief Executive Officer. Mr. Levine has been with
the Company for more than 38 years and is a member of the Company's Board of
Directors and Executive Committee.
Paul A. Veteri became President and Chief Operating Officer, replacing Mr.
Levine. Mr. Veteri has been with the Company for more than 25 years and was
previously Executive Vice President and Chief Financial Officer. He is a member
of the Board of Directors and Executive Committee.
Peter J. Griffin was elected Vice President Finance and Controller and serves as
Chief Financial Officer. He was previously Vice President and Controller. Mr.
Griffin has been with the Company for over 25 years.
* * *
We appreciate the ongoing trust and confidence of the consumers and
professionals who use our products, and the loyal support of our employees,
shareholders and suppliers. We thank them for their interest and confidence in
Carter-Wallace.
Ralph Levine
Chairman of the Board and
Chief Executive Officer
Paul A. Veteri
President and
Chief Operating Officer
June 15, 2001
6
Carter-Wallace, Inc. and Subsidiaries
SUMMARY OF SELECTED FINANCIAL DATA
- --------------------------------------------------------------------------------
YEARS ENDED MARCH 31
----------------------------------------------------------------
2001 2000 1999 1998 1997
----------------------------------------------------------------
(IN THOUSANDS, EXCEPT PER SHARE AND EMPLOYEE DATA)
OPERATIONS
Net sales $222,727 $207,866 $182,845 $190,768 $167,233
Earnings (loss) from continuing operations
before taxes (5,091) 2,313 (7,023) 2,459 25
Earnings (loss) from continuing operations (334) 1,359 (3,133) 1,198 (398)
Earnings from discontinued operations 49,556 41,973 31,342 26,103 27,154
-------- -------- -------- -------- --------
Net earnings 49,222 43,332 28,209 27,301 26,756
Earnings (loss) per share from continuing
operations--basic $ (.01) $ .03 $ (.07) $ .02 $ (.01)
Earnings per share from discontinued
operations--basic 1.10 .93 .69 .57 .59
-------- -------- -------- -------- --------
Earnings per share--basic 1.09 .96 .62 .59 .58
Earnings (loss) per share from continuing
operations--diluted $ (.01) $ .03 $ (.07) $ .02 $ (.01)
Earnings per share from discontinued
operations--diluted 1.05 .91 .69 .57 .59
-------- -------- -------- -------- --------
Earnings per share--diluted 1.04 .94 .62 .59 .58
Dividends per share $ .32 $ .24 $ .22 $ .16 $ .16
Average common shares outstanding 45,311 45,019 45,180 46,093 46,389
FINANCIAL POSITION
Working capital $240,123 $205,447 $159,549 $145,715 $142,972
Net property, plant and equipment 23,370 19,395 20,645 20,977 26,555
Total assets 659,663 642,103 595,762 588,438 596,289
Long-term debt 35,914 38,000 39,234 38,000 43,993
Stockholders' equity 420,537 391,038 359,156 349,650 349,154
OTHER DATA
Capital expenditures for continuing
operations $ 2,284 $ 2,055 $ 1,508 $ 2,318 $ 2,563
Book value per share 9.23 8.65 7.98 7.70 7.53
Number of employees 3,340 3,320 3,310 3,360 3,460
------------------------------------------------------
QUARTERLY DATA ON COMMON STOCK
The high and low selling prices of the Company's
common stock, principally traded on the New York Stock
Exchange (symbol CAR), for the two most recent fiscal
years were as follows:
FISCAL YEARS ENDED MARCH 31
------------------------------------------
2001 2000
-------------------- --------------------
HIGH LOW HIGH LOW
QUARTER ENDED --------- --------- --------- ---------
June 30 $23.69 $17.38 $18.25 $17.19
September 30 28.00 19.00 18.56 17.56
December 31 34.50 23.44 18.88 17.44
March 31 33.38 22.95 19.56 17.44
A dividend of $.08 per share was declared in all four
quarters of 2001. A dividend of $.06 per share was
declared in all four quarters of 2000.
7
PENDING SALE OF THE COMPANY
In May 2001 the Company announced it had entered into agreements for the sale of
the Company in a two-step transaction in which stockholders will receive $20.30
per share, subject to certain closing adjustments. This transaction is pending
at this time and is subject to approval by stockholders and other conditions.
Full details will be included in a proxy statement regarding this transaction
which will be sent to all stockholders.
In this two-step transaction, the consumer business, consisting of the Carter,
Lambert Kay and International Divisions, will be sold by the Company immediately
prior to the merger of the remainder of the Company. Accordingly, the consumer
business is included as a discontinued operation for all periods presented in
the March 31, 2001 financial statements.
NET EARNINGS
Net earnings were $49,222,000 in the year ended March 31, 2001, compared to net
earnings of $43,332,000 in the prior year. Basic earnings per share were $1.09
per share in the current year compared to $.96 per share in the prior year, an
increase of 14%. On a diluted basis, earnings per share were $1.04 per share,
compared to $.94 per share in the prior year, an increase of 11%.
The results for continuing operations related to the health care business, which
includes a substantial portion of corporate overhead, were a loss of $334,000 in
the current year compared with earnings of $1,359,000 in the prior year.
Earnings from discontinued operations related to the consumer business were
$49,556,000 in the current year, compared with $41,973,000 in the prior year.
CONTINUING OPERATIONS (HEALTH CARE BUSINESS)
Net sales from continuing health care operations were $222,727,000 in 2001, a
7.1% increase over the sales of $207,866,000 in the prior year. This increase
was due to higher selling prices as well as increased unit volume. The unit
volume increase was due largely to higher sales of Astelin Nasal Spray and
cough/cold products. Sales of most pharmaceutical products continue to be
adversely affected by generic competition.
In 2000, net sales from continuing health care operations were $207,866,000
compared to 1999 sales of $182,845,000, an increase of 14%. This improvement was
due to increased unit volume as well as higher selling prices. The unit volume
increase was due to the continued growth of Astelin Nasal Spray and the
introduction of several new cough/cold prescription products.
Cost of goods sold for continuing health care operations as a percentage of net
sales was 22.8% in 2001, 23.2% in 2000 and 25.3% in 1999. The variations from
year to year were due primarily to selling price increases in excess of cost
increases.
Advertising, marketing, other selling and distribution expenses for continuing
health care operations in 2001 decreased by $1,124,000 or 1.3% as a result of
reduced spending for pharmaceutical products. In 2000, advertising, marketing,
other selling and distribution expenses increased by $7,426,000 or 9.3% as a
result of costs associated with the introduction of a reformulated version of an
existing product and product introductions.
Research and development expenses for continuing health care operations in 2001
increased by $2,445,000 or 14.6% due to higher spending primarily for
taurolidine, a compound being tested to determine if it has clinically important
antineoplastic activity. In 2000, research and development expenses increased by
$2,006,000 or 13.6%, also due in part to spending for taurolidine.
General and administrative expenses for continuing operations, which includes a
substantial portion of corporate overhead, increased in 2001 by $11,603,000 or
21.7% versus the prior year due largely to an acceleration of certain pension
costs as a result of the retirement of the Company's former Chairman of the
Board and Chief Executive Officer and costs for legal and other professional
fees associated with the pending sale of the Company. Pension costs and
compensation related expense also increased. In 2000, general and administrative
expenses decreased by $1,284,000 or 2.3% due largely to non-recurring prior year
employee termination costs related to organizational changes.
Interest expense for continuing health care operations was $3,117,000 in 2001,
the same as in 2000. In 2000, interest expense decreased by $117,000 versus the
prior year.
Interest income for continuing health care operations increased in 2001 by
$4,106,000 from the prior year. In 2000, interest income was higher than 1999 by
8
MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL
CONDITION (CONTINUED)
- --------------------------------------------------------------------------------
$731,000. The increase in both years was due primarily to a higher level of
interest bearing investments.
Other expenses (income), net for continuing health care operations showed an
increase in expense of $10,981,000 in 2001. This increase was the result of
higher costs associated with the sharing of profits on a reformulated product,
increased non-cash charges related to incentive plans and a reduction in other
income related to ASTA Medica's share of joint venture operations. In 2000,
other expense increased by $6,326,000 due to higher non-cash charges related to
incentive plans and other miscellaneous expenses. In addition, other income
related to ASTA Medica's share of joint venture operations declined.
The income tax rate for continuing health care operations was a benefit of 93.5%
in 2001, which includes the elimination of a valuation reserve. In 2000, the tax
rate was a provision of 41.2% and in 1999 the rate was a benefit of 55.4%.
DISCONTINUED OPERATIONS (CONSUMER BUSINESS)
Net sales from discontinued consumer operations were $558,665,000 in 2001, a
3.5% increase over the sales of $539,802,000 in the prior year. This improvement
was due to increased unit volume, and to a lesser extent, higher selling prices.
Domestically, sales of Trojan condoms, Nair depilatories and First Response
pregnancy and ovulation test kits were all higher. Lower foreign exchange rates
had the effect of decreasing sales in the current year period by approximately
$22,000,000.
In 2000, net sales from discontinued consumer operations were $539,802,000
compared to 1999 sales of $486,027,000. This improvement was due to unit volume,
and to lesser extent, higher selling prices. Domestic condom sales increased
versus 1999 by 7.4%. Domestic anti-perspirant and deodorant sales increased by
7.2% in comparison to 1999. Domestic sales of Nair depilatories increased
significantly versus 1999. A portion of the unit volume increase was related to
the acquisition of the Barbara Gould line of skin care products in France and
product introductions. Lower foreign exchange rates had the effect of decreasing
sales in 2000 by approximately $10,400,000.
Cost of goods sold for discontinued consumer operations as a percentage of net
sales was 40.0% in 2001, 41.6% in 2000 and 42.6% in 1999. The variations from
year to year were due primarily to changes in product mix throughout this
period. The Company has taken steps to minimize the effects of higher costs by
selective price increases and cost control and reduction measures.
Advertising, marketing, other selling and distribution expenses for discontinued
consumer operations in 2001 increased by $4,270,000 or 2.1% as a result of
increased advertising and promotional support domestically. In 2000,
advertising, marketing, other selling and distribution expenses increased by
$18,379,000 or 10.1% largely as a result of higher spending in International
markets due in part to promotional support for the Barbara Gould product line
and product introductions.
Research and development expenses for discontinued consumer operations in 2001
decreased by $340,000 or 2.9%. In 2000, research and development expenses
increased by $656,000 or 5.9%.
General and administrative expenses for discontinued consumer operations
decreased in 2001 by $383,000 or 1.3% versus the prior year. In 2000, general
and administrative expenses decreased by $99,000 or 0.3%.
Interest expense for discontinued consumer operations was $1,277,000 in 2001, a
decrease of $220,000 versus 2000. In 2000, interest expense increased by
$239,000 versus the prior year. The fluctuation in interest expense is related
to levels of borrowing.
Interest income for discontinued consumer operations increased in 2001 by
$103,000 from the prior year. In 2000, interest income was lower than 1999 by
$85,000.
Other expenses (income), net for discontinued consumer operations included a
gain on the sale of a foreign facility. In 2000, other expenses (income), net
showed an increase in expense of $1,724,000, primarily in the International
Division.
The income tax rate for discontinued consumer operations was 42.2% in 2001,
38.9% in 2000 and 41.2% in 1999.
TAUROLIDINE
Research at independent facilities determined that taurolidine induced cell
death in numerous human cancer cells in vitro. These developments prompted the
Company to initiate an R&D program directed at multiple cancer cell lines to
determine if taurolidine has clinically important antineoplastic activity. An
9
MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL
CONDITION (CONTINUED)
- --------------------------------------------------------------------------------
Investigational New Drug Application (IND) was filed with and accepted by the
FDA. Clinical trials in patients with brain, ovarian and mesothelioma cancer are
in progress.
ASTELIN
In July 1998, the Company entered into a joint venture agreement with ASTA
Medica AG with an effective date of November, 1997. Under the terms of the
agreement the Company is responsible for all manufacturing, selling, marketing
and administrative activities for
Astelin and Depen, another product licensed from ASTA Medica AG, and receives
compensation for these activities from the joint venture. Included in other
expense (income), net is income of $140,000 in 2001, $3,981,000 in 2000 and
$6,782,000 in 1999 related to ASTA Medica's share of joint venture operations.
FELBATOL (FELBAMATE)
As previously reported, in the years ended March 31, 1995 and 1996 the Company
incurred one-time charges to pre-tax earnings totaling $45,980,000 related to
use restrictions for Felbatol. Depending on future sales levels, additional
inventory write-offs may be required. If for any reason the product at some
future date should no longer be available in the market, the Company will incur
an additional one-time charge consisting primarily of inventory write-offs and
anticipated returns of product currently in the market, in the range of
$15,000,000 on a pre-tax basis.
LIQUIDITY AND CAPITAL RESOURCES
Funds provided from operations and the Company's short-term investments and cash
equivalents are the main source for financing working capital requirements,
additions to property, plant and equipment, the payment of dividends and the
purchases of treasury stock. External borrowings are incurred as needed to
satisfy cash requirements related to seasonal business fluctuations and to
finance major facility expansion programs and major acquisitions.
At March 31, 2001, the continuing health care operation had available various
bank credit lines amounting to $110,000,000. The lines are made up of a
$100,000,000 revolving credit facility and $10,000,000 in an uncommitted
credit line.
In June 2000, Carter-Wallace, Inc. entered into an agreement to sell two parcels
of vacant land adjacent to its Cranbury, New Jersey facility totaling
approximately 210 acres. The closings of these transactions are contingent upon
certain approvals being obtained and the satisfactory resolution of other
conditions. No assurance can be given that the closings will take place. The
total proceeds from these land sales would be approximately $22,050,000, less
commissions and other expenses. The cost basis for the land subject to sale is
approximately $1,000,000.
Under stock repurchase programs approved by the Company's Board of Directors,
the Company purchased 246,000 shares at a cost of $3,885,000 in the year ended
March 31, 1999.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT FINANCIAL MARKET RISK
A portion of the Company's discontinued operations are exposed to changes in
foreign exchange rates. Where practical, the Company seeks to relate expected
local currency revenues with local currency costs and local currency assets with
local currency liabilities.
The Company's interest bearing investments and a portion of its debt in
discontinued operations are subject to interest rate risk. Changes in interest
rates could affect interest income and expense in future periods. The Company
invests on a short-term basis.
There has been no material impact on operations from financial market risk
exposure during the year ended March 31, 2001.
CAPITAL EXPENDITURES
Capital expenditures related to continuing health care operations were
$2,284,000 in 2001, $2,055,000 in 2000, and $1,508,000 in 1999. Capital
expenditures related to discontinued consumer operations were $11,778,000 in
2001, $16,001,000 in 2000 and $15,763,000 in 1999.
10
DESCRIPTION OF BUSINESS
- --------------------------------------------------------------------------------
The Company is engaged in the manufacture and sale of a diversified line of
products as described below. As a result of the pending sale of the Company,
domestic consumer products and all international products are considered
discontinued operations in the consolidated financial statements.
DOMESTIC CONSUMER PRODUCTS
These products are promoted directly to the consumer by television and other
advertising media and are sold to wholesalers and various retailers. They are
manufactured and sold by our consumer products divisions and some are sold
throughout the rest of the world by various subsidiaries and distributors.
Principal products include:
* Arrid Extra Dry and Arrid XX anti-perspirants and deodorants
* Lady's Choice anti-perspirants and deodorants
* Answer and First Response at-home pregnancy and ovulation test kits; First
Response pregnancy planning kit and urinary tract infection kit
* Carter's laxative
* H-R lubricating jelly
* Nair depilatories, waxes and bleach
* Pearl Drops whitening toothpolish and whitening toothpaste
* Rigident denture adhesive
* Trojan, Class Act, Naturalamb and Supra condoms
* Boundary dog and cat repellants
* Fresh 'n Clean grooming products,
stain and odor remover and puppy housebreaking pads
* Lassie and Tiny Tiger pet product lines
* Linatone food supplement
* Twinco chain collars and leads, nail trimmers, slicker brushes and combs
* Mr. Spats' cat toys
DOMESTIC HEALTH CARE
Health care products are promoted primarily to physicians, pharmacists,
hospitals, laboratories and clinics by a staff of specially trained professional
sales representatives and by advertising in professional journals. These
products are manufactured and sold by our professional products divisions and
some are sold throughout the rest of the world by various subsidiaries and
distributors. Principal products include:
* Astelin Nasal Spray for the treatment of symptoms of seasonal allergic
rhinitis and vasomotor rhinitis
* Felbatol for the treatment of seizures associated with epilepsy
* Organidin NR family of expectorants/antitussives
* Ryna line of cough/cold products
* Tussi-12 cough/cold product
* Soma brand muscle relaxants
* Butisol sedative hypnotic
* Depen penicillamine for severe rheumatoid arthritis
* Doral sedative hypnotic
* Lufyllin xanthine bronchodilator
* Maltsupex laxative
* Analyst physician office chemistry system
* Clearview product line of rapid tests for the determination of pregnancy,
group A streptococcus, chlamydia and C. difficile
* Prevue and Status rapid tests to aid in the determination of pregnancy
* Wampole and other branded enzyme and fluorescent immunoassay tests to detect
a broad range of infectious and autoimmune diseases
* Isostat product line to aid in the detection of micro-organisms in blood
* MicroTrak line of immunoassay products for the detection of sexually
transmitted diseases, primarily chlamydia
* Mono-Test, Mono-Latex and Mono-plus for the detection of mononucleosis
* Stat-Crit portable instrument for use in measuring blood hematocrit levels
--------------------------
INTERNATIONAL
In addition to many of the products listed above, the Company sells the
following products exclusively in certain International markets:
* Anne French facial cleansing products
* Barbara Gould facial beauty and cleansing products
* Bi-Solution acne treatment products
* Cerox adhesive tapes and bandages
* Confidelle, Discover and Gravix at-home pregnancy test kits
* Cossack line of men's grooming products
* Curash line of skin care products
* Email Diamant toothpastes
* Eudermin line of skin care and toiletry products
* Femfresh line of feminine hygiene products
* GranVista non-prescription eyeglasses
* Lineance line of anti-cellulite and associated skin care products
* Odontovax line of oral hygiene products
* Orasiv denture adhesive
* Poupina line of skin care and toiletry products
* Taky depilatories and waxes
* Ultrafresh mouthwash and breath freshening products
* Antiphlogistine Rub A-535 and Dencorub topical analgesics
* Atasol analgesic/antipyretic
* Bentasil medicated throat lozenges
* Cerulisina otic solution
* Diovol antacid products
* Gravol antinauseant
* Jordan toothbrushes
* Maltlevol and Pangavit vitamin supplements
* Ovol antiflatulent
* Sterimar nasal decongestant
* Technogenetics line of diagnostic tests for thyroid metabolism,
fertility/pregnancy conditions and other hormonal (endocrine) disorders
11
Carter-Wallace, Inc. and Subsidiaries
CONSOLIDATED BALANCE SHEETS
AT MARCH 31, 2001 AND 2000
ASSETS 2001 2000
- -----------------------------------------------------------------------------------------------------------
CURRENT ASSETS
Cash and cash equivalents $ 84,316,000 $ 54,612,000
Short-term investments 47,891,000 41,150,000
Accounts receivable-trade, less allowances of
$1,485,000 in 2001 and $1,663,000 in 2000 29,314,000 28,804,000
Other receivables 2,107,000 3,736,000
Inventories
Finished goods 7,409,000 12,026,000
Work in process 1,966,000 1,569,000
Raw materials and supplies 9,627,000 6,895,000
------------ ------------
19,002,000 20,490,000
------------ ------------
Deferred taxes 14,219,000 19,409,000
Prepaid expenses and other current assets 3,472,000 5,234,000
Net current assets of discontinued consumer operations held
for sale 113,808,000 111,597,000
------------ ------------
TOTAL CURRENT ASSETS 314,129,000 285,032,000
------------ ------------
PROPERTY, PLANT AND EQUIPMENT, AT COST
Land 2,076,000 1,778,000
Buildings and improvements 5,260,000 5,713,000
Machinery, equipment and fixtures 43,900,000 32,437,000
Leasehold improvements 17,935,000 17,888,000
------------ ------------
69,171,000 57,816,000
Accumulated depreciation and amortization 45,801,000 38,421,000
------------ ------------
23,370,000 19,395,000
------------ ------------
INTANGIBLE ASSETS
Excess of purchase price of businesses acquired over the
net assets at date of acquisition, less amortization 16,546,000 18,110,000
Patents, trademarks, contracts and formulae, less
amortization 15,318,000 14,070,000
------------ ------------
31,864,000 32,180,000
------------ ------------
DEFERRED TAXES 35,999,000 36,473,000
NET NONCURRENT ASSETS OF DISCONTINUED CONSUMER OPERATIONS
HELD FOR SALE 182,478,000 190,987,000
OTHER ASSETS 71,823,000 78,036,000
------------ ------------
$659,663,000 $642,103,000
============ ============
See accompanying notes to consolidated financial statements.
12
LIABILITIES AND STOCKHOLDERS' EQUITY 2001 2000
- -----------------------------------------------------------------------------------------------------------
CURRENT LIABILITIES
Accounts payable $ 4,176,000 $ 4,795,000
Accrued expenses 63,934,000 65,561,000
Notes payable 300,000 1,424,000
Taxes on income 5,596,000 7,805,000
------------ ------------
TOTAL CURRENT LIABILITIES 74,006,000 79,585,000
------------ ------------
LONG-TERM LIABILITIES
Long-term debt 35,914,000 38,000,000
Deferred compensation 15,500,000 26,647,000
Accrued postretirement benefit obligation 68,691,000 67,425,000
Other long-term liabilities 45,015,000 39,408,000
------------ ------------
TOTAL LONG-TERM LIABILITIES 165,120,000 171,480,000
------------ ------------
TOTAL LIABILITIES 239,126,000 251,065,000
------------ ------------
STOCKHOLDERS' EQUITY
Preferred stock, authorized 1,000,000 shares,
without par value; issued--none -- --
Common stock, authorized 80,000,000 shares,
par value $1 per share, one vote per share; issued
34,827,000 shares in 2001 and 34,776,000 shares in 2000 34,827,000 34,776,000
Class B common stock, authorized 13,056,800 shares, par
value $1 per share, ten votes per share; issued 12,378,000
shares in 2001 and 12,429,000 in 2000 12,378,000 12,429,000
Capital in excess of par value 4,536,000 4,231,000
Retained earnings 435,341,000 400,616,000
Less:
Accumulated other comprehensive loss
Foreign currency translation adjustment 39,658,000 31,385,000
Treasury stock at cost--1,494,500 common and 153,600
Class B common shares in 2001 and 1,857,900 common
and 153,600 Class B common shares in 2000 26,887,000 29,629,000
------------ ------------
TOTAL STOCKHOLDERS' EQUITY 420,537,000 391,038,000
------------ ------------
$659,663,000 $642,103,000
============ ============
See accompanying notes to consolidated financial statements.
13
Carter-Wallace, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF
EARNINGS, RETAINED EARNINGS AND
COMPREHENSIVE EARNINGS
THREE YEARS ENDED MARCH 31, 2001
2001 2000 1999
- ---------------------------------------------------------------------------------------------------------------
CONSOLIDATED STATEMENTS OF EARNINGS
Net sales $222,727,000 $207,866,000 $182,845,000
Cost of goods sold 50,772,000 48,306,000 46,247,000
------------ ------------ ------------
Gross Profit 171,955,000 159,560,000 136,598,000
------------ ------------ ------------
Operating expenses:
Advertising and promotion 32,864,000 36,260,000 33,090,000
Marketing and other selling 50,051,000 47,584,000 43,477,000
Distribution expense 3,040,000 3,235,000 3,086,000
Research and development 19,207,000 16,762,000 14,756,000
General and administrative 64,961,000 53,358,000 54,642,000
Interest expense 3,117,000 3,117,000 3,234,000
Interest income (9,040,000) (4,934,000) (4,203,000)
Other expense (income), net 12,846,000 1,865,000 (4,461,000)
------------ ------------ ------------
177,046,000 157,247,000 143,621,000
------------ ------------ ------------
Earnings (loss) from continuing operations before
provision (benefit) for taxes on income (5,091,000) 2,313,000 (7,023,000)
Provision (benefit) for taxes on income (4,757,000) 954,000 (3,890,000)
------------ ------------ ------------
Earnings (loss) from continuing operations (334,000) 1,359,000 (3,133,000)
Discontinued consumer operations:
Income from discontinued consumer operations, net of
tax of $36,226,000, $26,750,000 and $21,925,000 in
2001, 2000 and 1999, respectively 49,556,000 41,973,000 31,342,000
------------ ------------ ------------
Net earnings $ 49,222,000 $ 43,332,000 $ 28,209,000
============ ============ ============
Earnings (loss) per share--basic:
Continuing operations $ (0.01) $ 0.03 $ (0.07)
Discontinued consumer operations 1.10 0.93 0.69
------------ ------------ ------------
$ 1.09 $ 0.96 $ 0.62
============ ============ ============
Earnings (loss) per share--diluted:
Continuing operations $ (0.01) $ 0.03 $ (0.07)
Discontinued consumer operations 1.05 0.91 0.69
------------ ------------ ------------
$ 1.04 $ 0.94 $ 0.62
============ ============ ============
CONSOLIDATED STATEMENTS OF RETAINED EARNINGS
Amount at beginning of year $400,616,000 $368,093,000 $349,815,000
Net earnings 49,222,000 43,332,000 28,209,000
------------ ------------ ------------
449,838,000 411,425,000 378,024,000
Dividends--$.32 per share in 2001, $.24 per share
in 2000 and $.22 per share in 1999 (14,497,000) (10,809,000) (9,931,000)
------------ ------------ ------------
Amount at end of year $435,341,000 $400,616,000 $368,093,000
============ ============ ============
CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS
Net earnings $ 49,222,000 $ 43,332,000 $ 28,209,000
Other comprehensive (loss)
Foreign currency translation adjustment (8,273,000) (3,600,000) (2,974,000)
------------ ------------ ------------
Total comprehensive earnings $ 40,949,000 $ 39,732,000 $ 25,235,000
============ ============ ============
See accompanying notes to consolidated financial statements.
14
CONSOLIDATED STATEMENTS OF
CASH FLOWS
THREE YEARS ENDED MARCH 31, 2001
2001 2000 1999
- -------------------------------------------------------------------------------------------------------------
Net earnings $ 49,222,000 $ 43,332,000 $ 28,209,000
Adjustments to reconcile net earnings to cash flows
provided by (used in) operating activities:
Income from discontinued consumer operations, net of
tax (49,556,000) (41,973,000) (31,342,000)
Cash payments for one-time charges (727,000) (1,252,000) (2,318,000)
Depreciation and amortization 3,811,000 4,069,000 4,003,000
Amortization of excess of purchase price of
businesses acquired over the net assets at date
of acquisition, patents, trademarks, contracts,
and formulae 12,319,000 8,981,000 6,302,000
Other changes in assets and liabilities:
Decrease (increase) in accounts receivable and
other receivables 1,119,000 9,980,000 (1,156,000)
Decrease (increase) in inventories 1,488,000 (3,199,000) (2,334,000)
Decrease in deferred taxes 5,664,000 2,726,000 1,528,000
Decrease (increase) in prepaid expenses 1,762,000 644,000 (2,712,000)
(Decrease) increase in accounts payable and
accrued expenses (3,626,000) 871,000 (2,660,000)
(Decrease) increase in deferred compensation (11,249,000) 6,564,000 2,548,000
Other changes 5,017,000 (7,798,000) (5,235,000)
------------ ------------ ------------
Cash flows provided by (used in) operating activities 15,244,000 22,945,000 (5,167,000)
------------ ------------ ------------
Cash flows used in investing activities:
Additions to property, plant and equipment (2,284,000) (2,055,000) (1,508,000)
(Increase) in short-term investments (6,784,000) (9,502,000) (5,960,000)
------------ ------------ ------------
Cash flows used in investing activities (9,068,000) (11,557,000) (7,468,000)
------------ ------------ ------------
Cash flows used in financing activities:
Dividends paid (14,497,000) (10,809,000) (9,931,000)
Payments of debt (3,210,000) (207,000) (4,480,000)
Purchase of treasury stock (5,861,000) (492,000) (4,381,000)
Proceeds from exercised stock options 787,000 -- --
------------ ------------ ------------
Cash flows used in financing activities (22,781,000) (11,508,000) (18,792,000)
------------ ------------ ------------
Effect of foreign exchange rate changes on cash and cash
equivalents (751,000) 212,000 371,000
------------ ------------ ------------
Net cash provided by discontinued consumer operations 47,060,000 17,436,000 26,724,000
------------ ------------ ------------
Increase (decrease) in cash and cash equivalents $ 29,704,000 $ 17,528,000 $ (4,332,000)
============ ============ ============
See accompanying notes to consolidated financial statements.
15
Carter-Wallace, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
1. DESCRIPTION OF BUSINESS
On May 7, 2001, Carter-Wallace, Inc. (the "Company") entered into definitive
agreements for the sale of the Company in a two-step transaction. In accordance
with an Asset Purchase Agreement, the Company will first sell the net assets and
business of the Company's consumer business for $739 million, less certain debt
outstanding. Such funds will be paid directly to Carter-Wallace, Inc. Pursuant
to an Agreement and Plan of Merger, immediately following the sale of the
consumer business, the buying group will acquire the Company's outstanding
common stock and Class B common stock for $20.30 per share subject to certain
closing adjustments. CPI Development Corporation, a private holding company that
controls approximately 83% of the voting power of Carter-Wallace, Inc., has
entered into an agreement to vote in favor of the merger, subject to certain
limited exceptions. The aggregate consideration from both transactions is
estimated to be $1.121 billion, less approximately $160 million of corporate
taxes to be paid on the sale of the consumer business. Each agreement is
conditioned on the other, so one will not be completed without the other.
The asset sale and merger have been approved by the Board of Directors of each
party to the agreements and are subject to certain conditions, including a
financing condition for each buyer, various regulatory approvals, and the
approval of Carter-Wallace, Inc. stockholders.
The accompanying consolidated financial statements of Carter-Wallace, Inc. and
subsidiaries reflect the net assets and operations of the consumer business (as
defined in the aforementioned definitive agreements) as discontinued operations
and have been prepared in accordance with accounting principles generally
accepted in the United States of America. The consumer business has no separate
legal status and operates as an integral part of Carter-Wallace, Inc.'s overall
operations. The continuing health care business includes the accounts of the
Wallace Laboratories Division, the Wampole Laboratories Division, and all
corporate accounts not specifically identified in the definitive agreement as
part of the consumer business of Carter-Wallace, Inc.
Products sold by the health care business primarily include prescription
pharmaceuticals, as well as professional diagnostic products. These products are
promoted to physicians, pharmacists, hospitals, laboratories, and clinics by a
staff of specially trained professional sales representatives and by advertising
in professional journals.
Corporate income and expenses not identified to the consumer business remain in
the continuing health care business. Such corporate income and expenses include
the general corporate management of Carter-Wallace, Inc. and certain other
general corporate functions.
Cash, cash equivalents, and short-term investments in Canada, with the exception
of U.S. $1,000,000, are included in the assets of continuing operations.
Certain expenses such as postretirement benefit costs for consumer business
employees have been excluded from the consolidated statements of earnings from
continuing operations. However, the related assets and/or liabilities have been
included in the assets and liabilities of continuing operations because such
assets and/or liabilities will be retained by the continuing operations.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying consolidated financial statements have been prepared in
conformity with accounting principles generally accepted in the United States of
America. The assets, liabilities, and results of operations of the consumer
business have been presented as discontinued operations.
Revenue Recognition Policy
Revenue is recognized when products are shipped.
Use of Estimates
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and use assumptions
that affect certain reported amounts and disclosures. Actual amounts may differ.
Cash Equivalents and Short-term Investments
Cash equivalents consist of short-term securities with maturities of three
months or less when purchased. Investments with a maturity greater than three
months but less than one year are classified as short-term investments. The
carrying value of cash equivalents and short-term investments approximated fair
value at March 31, 2001 and 2000.
Inventories
Inventories are valued at the lower of cost or market on the first-in, first-out
(FIFO) method. Felbatol inventories of $4,078,000 and $6,387,000 at March 31,
2001 and 2000, respectively, not expected to be sold in the next fiscal year,
are included in other assets.
Property, Plant and Equipment
Depreciation is provided over the estimated useful lives of the assets,
principally using the straight-line method.
16
Machinery, equipment, and fixtures are depreciated over a period ranging from
five to twenty years. Buildings and improvements are depreciated over a period
ranging from twenty to forty years. Leasehold improvements are amortized on a
straight-line basis over the life of the related asset or the life of the lease,
whichever is shorter. Expenditures for renewals and betterments are capitalized.
Upon sale or retirement of assets, the appropriate asset and related accumulated
depreciation accounts are adjusted and the resultant gain or loss is reflected
in earnings. Maintenance and repairs are charged to expense as incurred.
Intangible Assets
The excess of purchase price of businesses acquired over the net assets at date
of acquisition is assessed to the product or group of products which constitutes
the business acquired and is amortized over no longer than 40 years for amounts
relating to acquisitions subsequent to October 31, 1970. The cost of patents,
formulae, and contracts is amortized on a straight-line basis over their legal
or contractual lives. The cost of trademarks is being amortized over no longer
than 40 years for amounts relating to acquisitions subsequent to October 31,
1970. Amounts related to intangibles acquired prior to October 31, 1970 are not
material.
The policy of the Company in assessing the recoverability of intangible assets
is to compare the carrying value of the intangible asset with the undiscounted
cash flow generated by products related to the intangible asset. In addition,
the Company continually evaluates whether adverse developments indicate that an
intangible asset may be impaired.
Income Taxes
Deferred income taxes are determined using the liability method based on the
estimated future tax effects of differences between the financial statement and
tax bases of assets and liabilities given the provisions of enacted tax laws.
Advertising and Marketing Costs
Advertising, promotion and other marketing costs are charged to earnings in the
period in which they are incurred.
Accrued Expenses
Accruals related to certain employee costs such as management bonuses and
vacation pay are calculated upon specifically identified employees for each of
the businesses.
Foreign Currency Translation
The assets and liabilities of foreign subsidiaries are translated at the
year-end rate of exchange, and income statement items are translated at the
average rates prevailing during the year. The resulting translation adjustment
is recorded as a component of stockholders' equity. The effects of foreign
exchange gains and losses arising from these translations of assets and
liabilities are included as a component of other comprehensive income. All of
the accumulated other comprehensive loss and foreign currency translation
adjustment included in stockholders' equity as of March 31, 2001 and 2000
relates to the discontinued operations of the consumer business.
New Accounting Pronouncement
In June 1998, the Financial Accounting Standards Board ("FASB") issued Statement
of Financial Accounting Standards (SFAS) No. 133, "Accounting for Derivative
Instruments and Hedging Activities." This statement requires that companies
recognize all derivatives as either assets or liabilities on the balance sheet
and measure these instruments at fair value. In June 1999, the FASB issued SFAS
No. 137, "Accounting for Derivative Instruments and Hedging Activities--Deferral
of the Effective Date of FASB Statement No. 133." This statement deferred the
effective date of SFAS No. 133 to fiscal years beginning after June 15, 2000. In
June 2000, the FASB issued SFAS No. 138, "Accounting for Certain Derivative
Instruments and Certain Hedging Activities," which made minor amendments to SFAS
No. 133. The Company will adopt SFAS No. 133, as amended, effective April 1,
2001. The adoption of this accounting requirement is not expected to have a
material effect on the Company's consolidated financial statements.
Earnings Per Common Share
Basic earnings per share is based on the average number of common and Class B
common shares outstanding during the year: 45,311,000 in 2001, 45,019,000 in
2000 and 45,180,000 in 1999. In computing diluted earnings per share,
incremental shares issuable upon the assumed exercise of stock options and the
vesting of stock awards have been added to the average shares outstanding.
Incremental shares for purposes of calculating diluted earnings per share
amounted to 2,236,900 in 2001, 1,033,200 in 2000 and 688,500 in 1999.
3. PROPERTY, PLANT, AND EQUIPMENT
Included in property, plant, and equipment are all operating assets related
directly to the health care business as well as certain corporate assets that
will remain with the health care business. The manufacturing facilities include
the pharmaceutical plant in Decatur, Illinois.
Specifically included with the health care business is the vacant land in
Cranbury, New Jersey. The vacant land consists of plots which are currently
under contract to be sold and other vacant land available for sale. In June
2000, Carter-Wallace, Inc. entered into an agreement to sell two parcels of
vacant land adjacent to its Cranbury, New Jersey facility totaling approximately
210 acres. The closings of
17
these transactions are contingent upon certain approvals being obtained and the
satisfactory resolution of other conditions. No assurance can be given that the
closings will take place. The total proceeds from these land sales would be
approximately $22,050,000, less commissions and other expenses. The cost basis
for the land subject to sale is approximately $1,000,000.
Also included with the continuing health care business are nonoperating
facilities in Trenton, New Jersey and Winsted, Connecticut. The costs of the
Trenton and Winsted facilities have been written off.
4. TAXES ON INCOME FROM CONTINUING OPERATIONS
The provision (benefit) for taxes on income from continuing operations was as
follows:
2001 2000 1999
----------- ----------- -----------
Current:
Domestic $(9,665,000) $ 2,022,000 $(4,473,000)
Foreign 265,000 158,000 201,000
----------- ----------- -----------
(9,400,000) 2,180,000 (4,272,000)
----------- ----------- -----------
Deferred:
Domestic 4,643,000 (1,226,000) 382,000
Foreign -- -- --
----------- ----------- -----------
4,643,000 (1,226,000) 382,000
----------- ----------- -----------
Total $(4,757,000) $ 954,000 $(3,890,000)
=========== =========== ===========
Deferred income taxes are provided for temporary differences between the
financial statement and tax bases of the assets and liabilities of the
continuing health care business. The temporary differences gave rise to the
following deferred tax assets and liabilities of the continuing operations at
March 31:
2001 2000
----------- -----------
Postretirement benefit plans $29,609,000 $28,968,000
Employee benefit plans (2,778,000) 8,430,000
Accrued liabilities 11,826,000 11,467,000
Asset valuation accounts 13,985,000 14,061,000
All other 4,878,000 4,824,000
Valuation allowances -- (3,247,000)
----------- -----------
Total deferred tax assets 57,520,000 64,503,000
----------- -----------
Depreciation (3,501,000) (3,946,000)
All other (3,801,000) (4,675,000)
----------- -----------
Total deferred tax liabilities (7,302,000) (8,621,000)
----------- -----------
Net deferred tax assets $50,218,000 $55,882,000
----------- -----------
Realization of the deferred tax assets of the continuing operations is dependent
on the consolidated Carter-Wallace, Inc. group generating sufficient taxable
income in future years. Although realization is not assured, management believes
it is more likely than not that all of the deferred tax assets will be realized.
However, the deferred tax assets could be reduced if estimates of future taxable
income are lowered. A valuation allowance is provided when it is more likely
than not that some portion of the deferred tax assets will not be realized.
18
The effective tax rate of the provision (benefit) for taxes on income from
continuing operations as compared with the U.S. Federal statutory income tax
rate was as follows:
2001 2000 1999
----------------------- ----------------------- ------------------------
% TO % TO % TO
TAX PRE-TAX TAX PRE-TAX TAX PRE-TAX
AMOUNT INCOME AMOUNT INCOME AMOUNT INCOME
----------- ------ ---------- ------ ----------- ------
Computed tax expense (benefit) $(1,782,000) (35.0)% $ 810,000 35.0% $ (2,458,000) (35.0)%
Foreign income taxed at a
different effective rate 82,000 1.6 25,000 1.1 98,000 1.4
State income taxes, net of
federal tax benefit (1,003,000) (19.7) 433,000 18.7 (148,000) (2.1)
Amortization of intangibles 266,000 5.2 266,000 11.5 266,000 3.8
Other, principally adjustments to
prior provisions 927,000 18.2 (580,000) (25.1) (1,648,000) (23.5)
Reversal of valuation allowance (3,247,000) (63.8) -- -- -- --
----------- ----- ----------- ----- ------------ -----
Provision for taxes on income $(4,757,000) (93.5)% $ 954,000 41.2% $ (3,890,000) (55.4)%
=========== ===== =========== ===== ============ =====
The U.S. Internal Revenue Service completed its examination of Carter-Wallace,
Inc. and subsidiaries' tax returns through fiscal year 1995, resulting in no
material impact on Carter-Wallace, Inc. The statute of limitations for the
examination of Carter-Wallace, Inc. and subsidiaries' U.S. Federal income tax
return has expired for fiscal years 1996 and 1997.
5. NOTES PAYABLE AND LONG-TERM DEBT
Notes Payable
The current portion of long-term debt was $300,000, $1,424,000 and $397,000 at
March 31, 2001, 2000 and 1999, respectively.
The continuing health care business has available various bank credit lines
amounting to $110,000,000. The availability of the lines of credit is subject to
review by the banks involved. Commitment fees are immaterial.
Long-Term Debt
Long-term debt of continuing operations is summarized below:
MARCH 31, MARCH 31,
2001 2000
----------- -----------
Promissory notes, 7.62%, payable in equal annual
installments of $7,000,000 from December 21, 2003 through
December 21, 2007 $35,000,000 $35,000,000
City of Decatur, Illinois adjustable rate Industrial Revenue
Bond, repaid December 1, 2000 -- 3,000,000
Promissory Notes, 6.18%, payable no later than September 12,
2002 1,214,000 1,424,000
----------- -----------
36,214,000 39,424,000
Less current portion of long-term debt included in notes
payable (300,000) (1,424,000)
----------- -----------
$35,914,000 $38,000,000
=========== ===========
Certain of the Company's long-term debt agreements contain financial covenants
which require Carter-Wallace, Inc. to maintain a minimum level of net worth and
limit total long-term liabilities to a stated percentage of total
capitalization.
Maturities of long-term debt for fiscal years 2003 through 2006 are $914,000,
$7,000,000, $7,000,000 and $7,000,000, respectively.
With respect to the $35,000,000 notes, should the Company, of which the health
care business and the consumer business are parts, sell a substantial portion of
its assets, the holders of the notes have the right to redeem the notes at face
value plus a premium of approximately $4,000,000.
Carter-Wallace, Inc. has guaranteed the repayment of debt in the consumer
business of Carter-Wallace, Inc. in the amount of $19,800,000. This debt may be
called by the lender if Carter-Wallace, Inc. ceases to be the majority
stockholder of the borrowing subsidiaries in the consumer business.
19
Carter-Wallace, Inc. issued promissory notes, payable no later than September
12, 2002, in connection with the acquisition of the net assets of Youngs Drug
Products Corporation and affiliates. Prepayments of all or portions of the notes
are required as certain contractual conditions are satisfied.
The fair value of long-term debt of continuing operations including current
maturities was $37,047,000 and $36,080,000 at March 31, 2001 and 2000,
respectively.
6. COMMON STOCK, CLASS B COMMON STOCK AND CAPITAL IN EXCESS OF PAR VALUE
Carter-Wallace, Inc. has two classes of common stock with a par value of $1.00
per share. Class B common stock generally has ten votes per share on all matters
and votes as a class with common stock, which has one vote per share. The
transfer of Class B common stock is restricted; however, Class B common stock is
at all times convertible into shares of common stock on a share-for-share basis.
Common stock and Class B common stock have identical rights with respect to cash
dividends and upon liquidation.
Activity for the years ended March 31, 2001 and 2000 was as follows:
CLASS B CAPITAL IN
COMMON COMMON EXCESS OF
STOCK STOCK PAR VALUE
----------- ----------- ----------
Balance at March 31, 1999 $34,740,000 $12,465,000 $4,483,000
Conversion of Class B common stock to Common Stock 36,000 (36,000) --
Cost of treasury stock over market value at date of award
or issuance -- -- (252,000)
----------- ----------- ----------
Balance at March 31, 2000 34,776,000 12,429,000 4,231,000
Conversion of Class B common stock to Common Stock 51,000 (51,000) --
Cost of treasury stock under market value at date of award
or issuance -- -- 305,000
----------- ----------- ----------
Balance at March 31, 2001 $34,827,000 $12,378,000 $4,536,000
=========== =========== ==========
The cost of treasury stock over or under the market value of the stock on the
date of the award or issuance has been applied to capital in excess of par
value, as well as any tax benefit on the appreciation of deferred stock awards.
Shares issued from treasury stock for stock awards amounted to 546,000, 239,100
and 28,000 shares at a cost of $8,603,000, $3,703,000 and $429,000 in 2001, 2000
and 1999, respectively. Shares purchased and added to treasury stock amounted to
182,900, 27,700 and 274,400 shares at a cost of $5,861,000, $492,000 and
$4,381,000 in 2001, 2000 and 1999, respectively. In 1999, Carter-Wallace, Inc.
exchanged 155,500 shares with a value of $2,125,000 previously issued as
restricted stock awards for an equivalent number of deferred stock awards.
7. RETIREMENT PLANS AND OTHER POSTRETIREMENT BENEFITS (DOLLARS IN THOUSANDS)
The continuing operations of Carter-Wallace, Inc. have two noncontributory
pension plans consisting of the Employees Retirement Plan of Carter-Wallace,
Inc. ("qualified plan") and the Executive Pension Benefits Plan ("nonqualified
plan"). The qualified pension plan covers substantially all nonbargaining unit
employees with over one year of service. These plans cover domestic employees,
including employees who will be made available to the consumer business.
Obligations of the Retirement Plan for Bargaining Employees of Carter-Wallace,
Inc. and obligations of the foreign subsidiaries have been included in the net
assets of the discontinued consumer business.
The funding policy of the Company is to make annual contributions to the
qualified plan in amounts equal to the minimum required by applicable
regulations. The plan's assets are invested primarily in common stocks and
corporate and government bonds. The nonqualified plan is unfunded.
The Company also provides certain health care and insurance benefits for retired
employees. The cost of the benefits is accrued during the years the employees
render service until they attain full eligibility for those benefits.
Postretirement benefit obligations for all domestic employees are included in
the liabilities of continuing operations because Carter-Wallace, Inc. will
retain these obligations. However, expenses related to postretirement benefits
for domestic consumer business employees of $1,848,000 in fiscal 2001,
$1,756,000 in fiscal 2000 and $832,000 in fiscal 1999 are included in
discontinued consumer operations in the consolidated statements of earnings.
20
The components of the pension and postretirement benefit expense included in
earnings (loss) from continuing operations reflected in the accompanying
consolidated financial statements for the years ended March 31, 2001, 2000 and
1999 were as follows:
RETIREMENT PLANS OTHER POSTRETIREMENT BENEFITS
------------------------------ ------------------------------
2001 2000 1999 2001 2000 1999
-------- -------- -------- ------- ------- -------
Service cost $ 7,625 $ 7,528 $ 7,088 $ 1,668 $ 1,905 $ 1,887
Interest cost 14,091 11,948 11,489 3,992 3,632 3,679
Expected return on assets (19,413) (17,685) (16,062) -- -- --
Amortization of prior service cost 3,726 2,263 2,179 (472) (890) (3,258)
Amortization of transition cost (5) (1,786) (1,786) -- -- --
Amortization of actuarial loss (gain) (1,954) 84 42 (788) (465) (328)
Settlement loss 2,634 -- -- -- -- --
-------- -------- -------- ------- ------- -------
Benefit cost 6,704 2,352 2,950 4,400 4,182 1,980
Less cost for Consumer Business
employees charged to
discontinued operations -- -- -- (1,848) (1,756) (832)
-------- -------- -------- ------- ------- -------
Total benefit expense $ 6,704 $ 2,352 $ 2,950 $ 2,552 $ 2,426 $ 1,148
======== ======== ======== ======= ======= =======
The components of the changes in the benefit obligation for the years ended
March 31, 2001 and 2000 were as follows:
OTHER POSTRETIREMENT
RETIREMENT PLANS BENEFITS
------------------------- -------------------------
2001 2000 2001 2000
-------- -------- -------- --------
Benefit obligation at beginning of year $183,125 $181,067 $ 49,240 $ 56,490
Service cost 7,625 7,528 1,668 1,905
Interest cost 14,091 11,948 3,992 3,632
Amendments (3,220) 20,196 -- --
Actuarial gain (loss) 16,826 (25,410) 2,631 (9,650)
Benefits paid (28,646) (12,204) (3,134) (3,137)
-------- -------- -------- --------
Benefit obligation at end of year $189,801 $183,125 $ 54,397 $ 49,240
======== ======== ======== ========
The components of the changes in plan assets for the years ended March 31, 2001
and 2000 were as follows:
OTHER POSTRETIREMENT
RETIREMENT PLANS BENEFITS
------------------------- -------------------------
2001 2000 2001 2000
-------- -------- -------- --------
Fair value of plan assets at beginning of year $228,731 $211,921 -- --
Actual return on plan assets (859) 28,081 -- --
Employer contributions 18,495 933 $ 3,134 $ 3,137
Benefits paid (28,646) (12,204) (3,134) (3,137)
-------- -------- -------- --------
Fair value of plan assets at end of year $217,721 $228,731 -- --
======== ======== ======== ========
21
The following is a reconciliation of the funded status of the plans to the
accompanying consolidated balance sheets at March 31, 2001 and 2000:
OTHER POSTRETIREMENT
RETIREMENT PLANS BENEFITS
------------------------- -------------------------
2001 2000 2001 2000
-------- -------- -------- --------
Funded status $ 27,920 $ 45,606 $(54,397) $(49,240)
Unrecognized actuarial gain (38,391) (74,809) (13,995) (17,414)
Unrecognized prior service cost (income) 21,057 28,003 (299) (771)
Unrecognized transition amounts (5) (11) -- --
Minimum liability adjustment (6,146) (3,206) -- --
-------- -------- -------- --------
Prepaid (accrued) benefit cost $ 4,435 $ (4,417) $(68,691) $(67,425)
======== ======== ======== ========
Amounts recognized as assets and liabilities of continuing operations in the
accompanying consolidated balance sheets at March 31, 2001 and 2000 were as
follows:
OTHER POSTRETIREMENT
RETIREMENT PLANS BENEFITS
------------------------- -------------------------
2001 2000 2001 2000
-------- -------- -------- --------
Other assets $ 30,901 $ 26,350 -- --
Accrued expenses (6,279) (11,766) -- --
Long-term liabilities (20,187) (19,001) $(68,691) $(67,425)
Intangible assets 6,146 3,206 -- --
-------- -------- -------- --------
Net amount recognized $ 10,581 $ (1,211) $(68,691) $(67,425)
======== ======== ======== ========
Plan amendments made in fiscal 2000 included a change related to credited
service and a federally mandated actuarial change related to mortality tables.
At March 31, the only pension plan with an accumulated benefit obligation in
excess of plan assets was the non-qualified plan, which had no assets.
Information on this plan is as follows:
2001 2000
-------- --------
Projected Benefit Obligation $42,432 $44,841
======= =======
Accumulated Benefit Obligation $26,466 $30,765
======= =======
The principal assumptions used in determining 2001, 2000 and 1999 actuarial
values were:
Discount rate 6.75 - 8%
Rate of increase in compensation levels 4 - 6%
Expected long-term rate of return on plan assets 7 -10%
Expense for the employee savings plan included in continuing operations, under
which the Company matches the contributions of participating employees up to a
designated level was approximately $900,000 in 2001, 2000 and 1999.
The assumed health care cost trend rate used to measure the accumulated
postretirement benefit obligation for those over age 65 is 8% for 2001 trending
to 5% over a three year period. For those under age 65, the trend rate is 6.3%
for 2001 trending to 5% over a three year period. A 1% increase or decrease in
the assumed respective annual medical cost trend rate would change the
accumulated postretirement benefit obligation by approximately $2,500,000 and
the service and interest components of net postretirement benefit expense by
approximately $300,000.
8. LONG-TERM INCENTIVE PLANS
1977 Restricted Stock Award Plan
The plan, as amended, provides for awards of not more than 2,750,000 shares of
common stock, subject to adjustments for stock splits, stock dividends and other
changes in Carter-Wallace's capitalization, to key employees, to be issued
either immediately
22
after the award or at a future date. As a result of the three-for-one stock
split in April, 1992 and the issuance of the Class B common stock in 1987, the
2,750,000 shares of common stock provided for in the Plan have been adjusted to
5,593,154 shares. As provided in the Plan and subject to restrictions, shares
awarded may not be disposed of by the recipients for a period of five years from
the date of the award. Cash dividends on shares awarded are held by
Carter-Wallace, Inc. for the benefit of the recipients, subject to the same
restrictions as the award. Such dividends (without interest) are paid to the
recipients upon lapse of the restrictions. The cost of the awards, equal to the
fair market value at the date of award, is being charged to operations in equal
annual amounts over a five year period commencing at the date of the award.
Cumulative awards as of March 31, 2001 amount to 3,466,250 shares. There were no
new awards granted in any of the past three fiscal years.
The financial statements reflect the transfer of the awarded shares from
treasury stock as of the date of their issuance. For shares that have been
issued, the market value at the date of the awards was $540,000 and $708,000 in
fiscal 2000 and 1999, respectively. The cost of treasury stock for these awards
was $428,000 and $429,000 in fiscal 2000 and 1999, respectively.
1996 Long-Term Incentive Plan
The plan, as amended, provides for awards of not more than 9,000,000 shares of
common stock, subject to adjustment for stock splits, stock dividends, and other
changes in the capitalization of Carter-Wallace, Inc. to key employees, to be
issued either immediately after the award or at a future date. The awards
consist of restricted and/or deferred stock or options, or a combination
thereof. At March 31, 2001, 5,827,337 shares had been granted under the 1996
long-term incentive plan. Outstanding awards of deferred stock become fully
vested and outstanding options become immediately exercisable upon the
occurrence of a change in control of the Company.
Stock Options
Under the plan, both qualified and non-qualified options may be granted to key
executive employees at fair market value at the date of grant. The right to
exercise the options, in installments, commences one year from the date of grant
and expires ten years after that date. As permitted by Statement of Financial
Accounting Standards ("SFAS") No. 123, "Accounting for Stock-Based
Compensation", Carter-Wallace, Inc. has chosen to continue to account for
options granted under the plan using the intrinsic value method. Accordingly, no
compensation expense has been recognized for these options. Had the fair value
method of accounting, as defined in SFAS No. 123, been applied to the Company's
stock options, net income would have been reduced by approximately $3,810,000 or
$.08 per share in 2001, $4,510,000 or $.10 per share in 2000 and $3,390,000 or
$.08 per share in 1999. The weighted-average fair market value of options
granted was $7.86 and $7.71 in 2000 and 1999, respectively. No options were
granted in 2001. For purposes of fair market value disclosures, the fair market
value of an option grant was estimated on the date of grant using the
Black-Scholes option-pricing model with the following weighted-average
assumptions:
2001 2000 1999
-------- -------- --------
Risk-Free Interest Rate -- 6.3% 4.9%
Expected Life -- 8 yrs. 8 yrs.
Volatility -- 31.7% 35.4%
Dividend Yield -- 1.2% 1.1%
A summary of the status of stock options granted under the plan as of March 31,
2001, 2000 and 1999 and changes during the years ended on those dates is
presented below:
2001 2000 1999
-------------------------- -------------------------- --------------------------
WEIGHTED-AVG. WEIGHTED-AVG. WEIGHTED-AVG.
OPTION EXERCISE OPTION EXERCISE OPTION EXERCISE
SHARES PRICE SHARES PRICE SHARES PRICE
--------- -------- --------- -------- --------- ------
Outstanding April 1 4,303,629 $16.09 3,672,143 $15.70 2,479,601 $14.70
Granted -- -- 683,926 18.06 1,192,542 17.77
Exercised (57,240) 13.75 -- -- -- --
Forfeited (26,546) 15.39 (52,440) 14.38 -- --
--------- --------- ---------
Outstanding March 31 4,219,843 $16.12 4,303,629 $16.09 3,672,143 $15.70
========= ========= =========
23
The following table summarizes information about stock options outstanding at
March 31, 2001:
OPTIONS OUTSTANDING OPTIONS EXERCISABLE
------------------------------------------------------ ---------------------------------
RANGE OF NUMBER WEIGHTED-AVG. WEIGHTED-AVG. NUMBER WEIGHTED-AVG.
EXERCISE OUTSTANDING REMAINING EXERCISE EXERCISABLE EXERCISE
PRICES AT 3/31/01 LIFE PRICE AT 3/31/01 PRICE
---------- ---------- ---------- -------- --------- -------
$12.13 to
$19.69 4,219,843 6.9 years $16.12 3,183,010 $15.65
For shares issued upon exercise of options, the proceeds from the exercise of
the options was $787,000 in 2001. The cost of treasury stock for these option
exercises was $886,000. The difference between the exercise price and the cost
of treasury stock was included in capital in excess of par value.
Stock Awards
Restricted and/or deferred stock awards which are awarded subject to
restrictions, may not be disposed of by the recipient for a period of four years
from the date of the award. Cash dividends on shares awarded are held by
Carter-Wallace, Inc. for the benefit of the recipients, subject to the same
restrictions as the award. Such dividends (without interest) are paid to the
recipients upon lapse of the restrictions. The cost of the awards, equal to the
fair market value at the date of award, is being charged to operations in equal
annual amounts over the four-year vesting period commencing at the date of the
award. Amortization related to stock awards made under the 1996 Long Term
Incentive Plan and included in continuing operations amounted to $8,754,000 in
fiscal 2001, $5,173,000 in fiscal 2000 and $2,533,000 in fiscal 1999. The
amortization of awards made to certain executives, who have been identified as
consumer business employees, was charged to discontinued consumer operations and
amounted to $361,000 in fiscal 2001, $556,000 in fiscal 2000 and $327,000 in
fiscal 1999. If a recipient's employment terminates by reason of retirement,
death or permanent disability, the award would vest immediately with the
unamortized value of the award charged to operations at that time.
Award transactions in shares for the past three years were:
SHARES
--------------------------------------------------
2001 2000 1999
--------- --------- -------
Cumulative Awards--Beginning of
Year 1,552,700 909,053 606,689
New Awards -- 648,834 302,364
Forfeited Awards (2,446) (5,187) --
--------- --------- -------
Cumulative Awards--End of Year 1,550,254 1,552,700 909,053
========= ========= =======
The financial statements reflect the transfer of the awarded shares from
treasury stock as of the date of their issuance. Outstanding awards of 832,319
shares at March 31, 2001 will be issued at a future date no later than four
years from the date of the award. For shares that have been issued, the market
value at the date of the awards was $8,908,000 in 2001 and $2,911,000 in 2000.
The cost of treasury stock for these awards was $8,603,000 in 2001 and
$3,275,000 in 2000. The differences between the market value at the date of the
awards and the cost of the treasury stock were included in capital in excess of
par value.
9. SHORT-TERM INVESTMENTS
At March 31, 2001 and 2000, short-term investments were intended to be held to
maturity and have remaining maturities of less than one year. The amortized cost
approximated fair value. The amortized cost of certificates of deposit were
$3,417,000 and $19,649,000 at March 31, 2001 and 2000, respectively. The
amortized cost of commercial paper was $24,321,000 and $21,501,000 at March 31,
2001 and 2000, respectively. In addition, included at March 31, 2001 are
bankers' acceptances in the amount of $20,153,000.
24
10. RENTAL EXPENSE AND LEASE COMMITMENTS (DOLLARS IN THOUSANDS)
Continuing Health Care Operations
Rental expense for operating leases with a term greater than one year for 2001,
2000 and 1999 was as follows:
REAL PROPERTY
RENTAL REAL SUB-RENTAL NET REAL
EXPENSE PROPERTY INCOME PROPERTY
------- -------- ------------- --------
2001 $6,990 $(3,047) $3,943
2000 6,559 (2,929) 3,630
1999 6,294 (2,701) 3,593
The real property rental expense for 2001, 2000 and 1999 excludes approximately
$1,000 annually of rental costs which have been charged to the one-time charges
for restructuring of operations and facilities.
Minimum rental commitments under non-cancellable operating leases in effect at
March 31, 2001 were as follows:
REAL PROPERTY
MINIMUM RENTAL REAL SUB-RENTAL NET REAL
COMMITMENTS PROPERTY INCOME PROPERTY
-------------- -------- ------------- --------
2002 $ 7,816 $ (3,515) $4,301
2003 7,154 (3,515) 3,639
2004 7,141 (3,515) 3,626
2005 7,057 (3,515) 3,542
2006 8,037 (3,597) 4,440
2007 and thereafter 41,042 (19,443) 21,599
Included in the real property rental commitments indicated above is
approximately $13,400 of future rental costs which were included in the one-time
charges for restructuring of operations and facilities. These costs are
associated with the subleasing of office space on which the continuing health
care business holds a long-term lease.
Discontinued Consumer Operations
Rental expense for operating leases included in discontinued operations with a
term greater than one year for 2001, 2000 and 1999 was as follows:
RENTAL REAL EQUIPMENT
EXPENSE PROPERTY AND OTHER
------- -------- ---------
2001 $1,890 $7,320
2000 1,725 6,990
1999 1,726 6,837
Minimum rental commitments under noncancellable leases in effect at March 31,
2001 were as follows:
MINIMUM RENTAL REAL EQUIPMENT CAPITAL LEASE
COMMITMENTS PROPERTY AND OTHER OBLIGATIONS
-------------- -------- --------- -------------
2002 $ 1,617 $ 896 $ 275
2003 1,469 564 216
2004 601 249 203
2005 363 69 190
2006 94 15 127
2007 and thereafter 7 -- --
------
1,011
Less interest and executory cost (163)
------
Present value of minimum lease payments (of
which $213 is included in accrued expenses) $ 848
======
25
11. LITIGATION INCLUDING ENVIRONMENTAL MATTERS
Continuing Operations
Environmental Matters
In 1982, the United States Environmental Protection Agency ("EPA") advised
Carter-Wallace, Inc. and over 200 other companies that they may be potentially
responsible parties ("PRPs") under the Comprehensive Environmental Response,
Compensation and Liability Act ("CERCLA") with respect to waste deposited at the
former Lone Pine Landfill ("Lone Pine") in Freehold, New Jersey. In 1989 and
1991, respectively, the Company and approximately 122 other PRPs, without
admitting liability, entered into two consent decrees with EPA, agreeing to
conduct a cleanup of the Lone Pine, and that cleanup is in progress. The total
estimated cost of the cleanup, which will continue many years into the future,
is $104 million to $120 million in current dollars. In addition, on October 23,
1997 the Company and eight other PRPs entered into a third consent decree with
EPA, the Department of Interior, and New Jersey to resolve the government's
natural resource damage claims, which obligation could cost as much as $2
million. After factoring in past and expected recoveries from nonsettlors, the
net share of cleanup costs and natural resource damage claims (exclusive of
defense costs) to the Company is expected to be from $8 million to $10 million,
of which it has paid about $7 million through March 31, 2001.
In August 1989, the Company instituted suit in New Jersey state court against 22
of its liability insurers to recover, inter alia, the share of costs of the
Company at Lone Pine, including related legal defense costs. The Company reached
settlements in this case with 19 of the insurers. There is no remaining solvent
insurer in the case. The Company has received approximately $12.5 million in
settlement payments from its insurers. Except for a portion of its legal fees
incurred in pursuing its insurers for coverage, the Company expects to be fully
reimbursed for its share of past and currently estimated future cleanup and
natural resource damage costs at Lone Pine.
The Company and nine other settling PRPs are party to two actions in NJ state
court against a former cleanup contractor at Lone Pine concerning amounts
allegedly owed to that contractor. The first action was filed by the contractor
on July 7, 1995 against the settling PRPs (including the Company), who
subsequently filed counterclaims against the contractor. The Company and the
nine other settling PRPs brought a separate action against the contractor on
July 10, 1995. Both lawsuits were subsequently consolidated. A settlement was
reached in these cases wherein the settling PRPs paid $1,287,500 to the
contractor. The Company's share of that $1,287,500 was approximately $115,000.
These amounts are included in the cleanup cost estimate and the Company's
estimated share thereof set forth above.
The Company faces potential liability involving waste material generated by the
Lambert Kay division at its former manufacturing facility in Winsted,
Connecticut. In May 1991, the EPA issued special notice letters under the
Comprehensive Environmental Response, Compensation and Liability Act to Lambert
Kay and about 50 other PRPs notifying them of potential liability with respect
to waste deposited at the Barkhamsted-New Hartford landfill in Barkhamsted,
Connecticut. In September 1991, and in February 1994, the Company and 21 other
PRPs, without admitting liability, entered into consent agreements under which
the PRPs agreed to perform certain investigation and engineering evaluation work
at the site, including the remedial investigation and feasibility study, and to
reimburse EPA for certain costs. The estimated cost of this work is about $5.4
million. The share of this cost to the Company is estimated to be $190,000,
which includes an allowance for insolvency or nonpayment of other PRPs' shares.
Through March 31, 2001, the Company has paid or received credit for about
$175,000. In addition, the Company and other settling PRPs have sued certain
nonsettlors for their share of these costs and have obtained some settlement
recoveries. Based on preliminary information from the site investigation work
(which is not completed), the total cost for performing the current and future
work at Barkhamsted, including the site investigation work, is estimated to be
from $6 million to $32 million. In June 1995, the Connecticut legislature
authorized the issuance of bonds to pay for approximately $8 million of the
future cleanup costs at the site. The issuance of these bonds is expected to
reduce by that amount those cleanup costs subject to PRP funding. Based on
expected PRP participation in future cleanup work and other factors, the Company
anticipates that its share of projected cleanup costs subject to PRP funding
(including costs incurred to date) will be not more than 4% to 5% of total
cleanup costs, and that the total expenditure of the Company will, therefore,
range from about $250,000 to $1,500,000. Thus, although applicable environmental
law provides for joint and several liability for the cost of cleanup work, based
on present estimates, the Company believes that the other PRPs will pay
substantially all of their allocated percentage shares of cleanup costs.
The Company believes, based upon the information available at this time, that
the environmental matters discussed above will not have a material effect on its
financial statements.
26
Litigation
The Company, along with numerous other drug manufacturers, wholesalers, and
suppliers, was named in a series of class action suits, the first of which was
filed in August 1994 in the California Superior Court, San Francisco County.
These suits were brought on behalf of all California independent retail
pharmacists who had purchased any brand-name prescription drugs since August
1989. The complaint alleged that the defendants, including the Company, entered
into a conspiracy to fix prices for brand-name prescription drugs and gave lower
prices to certain favored purchasers, while the alleged favored prices were
denied to the plaintiffs. Plaintiffs are seeking injunctive relief and
unspecified trebled compensatory damages, restitution of unspecified amounts by
which defendants are alleged to be unjustly enriched, and litigation costs,
interest, and attorney's fees. Class certification of the price-fixing
conspiracy claims was granted by order dated June 23, 1995, establishing a class
of independent retail pharmacists and small chains with ten or fewer California
locations. An individual action brought by two mid-size chain pharmacies was
subsequently coordinated with the consolidated class action as an "add-on" case
asserting virtually identical claims and demands for relief. Plaintiffs in that
action have amended their complaint to seek class certification, which has not
been granted. There has been no activity in these cases since 1996 because of
the pendency of related actions brought under the Federal antitrust laws. These
cases have been settled or otherwise resolved by the Company with the exception
of one case as to which a settlement in principle has been reached and should be
finally resolved shortly.
The Company is subject to other legal actions arising out of its operations. The
Company believes, based on the opinion of counsel, that it has good defenses to
such actions and should prevail.
Discontinued Consumer Operations
Litigation
The consumer business is engaged in litigation with Tambrands Inc. ("Tambrands")
in the Supreme Court of the State and County of New York ("Supreme Court")
arising out of a patent infringement and misappropriation suit previously filed
against both companies in the United States District Court, Southern District of
New York, by New Horizons Diagnostics Corporation ("NHDC"), et al. The NHDC
suit, which was settled and discontinued in July 1996, asserted claims with
respect to certain "gold sol" technology (used in First Response and Answer home
pregnancy and ovulation predictor test kits) that the consumer business had
acquired from Tambrand's pursuant to a written purchase agreement in March 1990.
The consumer business paid an immaterial amount toward that settlement. In the
pending Supreme Court action, Tambrands seeks reimbursement from the consumer
business of an unspecified portion of the amount paid by Tambrands in settlement
of the NHDC suit, and for defense costs. Cross-motions for summary judgment have
been filed. The consumer business believes it has good defenses, under the terms
of the purchase agreement, to Tambrands' claim.
The consumer business is subject to other legal actions arising out of its
operations. The consumer business believes, based on the opinion of counsel,
that it has good defenses to such actions and should prevail.
12. EMPLOYMENT AGREEMENTS AND TERMINATION AND CHANGE IN CONTROL ARRANGEMENTS
Carter-Wallace, Inc. has entered into employment agreements with its present
Chairman of the Board and Chief Executive Officer and its President that provide
for payments equal to salary and bonus multiples, certain pension enhancements
and a gross-up of applicable excise taxes if the executives' employment is
terminated as specified in the agreements. Carter-Wallace, Inc. has also entered
into an employment agreement with its Vice President, Consumer Products U.S.
that provides for her employment through December 2003. The obligation with
regard to its Vice President, Consumer Products U.S. is expected to be assumed
as part of the acquisition of the consumer business. The Company has also
entered into a consulting agreement with its former Chairman of the Board and
Chief Executive Officer that provides for a specified payment if that agreement
is terminated.
Carter-Wallace, Inc. has also entered into agreements with certain executive
officers. These agreements also provide for payments equal to salary and bonus
multiples, certain pension enhancements and a gross-up of applicable excise
taxes if the executives' employment is terminated as specified in the agreements
after a change in control of the Company.
The payments required by these agreements, based on a termination under the
agreements of all of the executives, is approximately $100,000,000.
Pursuant to the long-term incentive plan, outstanding awards of restricted and
deferred stock become fully vested and outstanding options become immediately
exercisable upon the occurrence of a change in control as defined in the
agreements.
A change in control also results in the immediate vesting and payment of
benefits under the Executive Pension Benefits Plans and, in the case of certain
officers, the elimination of early retirement reductions.
The transactions disclosed in note 1 relating to the contemplated sale of the
consumer business and the Company meet the definition of a change in control as
defined in the various agreements.
27
13. ACCELERATION OF CERTAIN PENSION AND OTHER COSTS
Included in general and administrative expenses for the fiscal year ended March
31, 2001 is a pretax charge amounting to $6,110,000 related to the acceleration
of certain pension and other costs as a result of the retirement of Henry H.
Hoyt, Jr., the former Chairman of the Board and Chief Executive Officer of
Carter-Wallace, Inc., in December 2000.
14. FELBATOL (FELBAMATE)
As previously reported, in the years ended March 31, 1995 and 1996, the Company
incurred one-time charges to pretax earnings totaling $45,980,000 related to use
restrictions for Felbatol. Depending on future sales levels, additional
inventory write-offs may be required. If for any reason the product at some
future date should no longer be available in the market, the Company will incur
an additional one-time charge, consisting primarily of inventory write-offs and
anticipated returns of product currently in the market, in the range of
$15,000,000 on a pretax basis.
15. DISCONTINUED CONSUMER OPERATIONS HELD FOR SALE (DOLLARS IN THOUSANDS)
As described in note 1 of the consolidated financial statements, in May 2001,
the Company's Board of Directors approved an agreement to sell the Company in a
two-step transaction.
The consumer business, which is reflected as a discontinued operation, consists
of the Carter Division, Lambert Kay Division, and International Subsidiaries.
Summarized results of such discontinued operations for fiscal 2001, 2000 and
1999 are as follows:
YEARS ENDED MARCH 31
---------------------------------------------
2001 2000 1999
---- ---- ----
Net sales $558,665 $539,802 $486,027
Earnings before provision for tax income 85,782 68,723 53,267
Provision for taxes on income 36,226 26,750 21,925
Net earnings $ 49,556 $ 41,973 $ 31,342
In connection with the agreement to sell the consumer business, the Company
expects that a gain will be realized on the disposal of these operations.
The net assets of the discontinued consumer business operations in the March 31,
2001 and 2000 consolidated balance sheets are comprised of:
YEARS ENDED MARCH 31
-----------------------------
2001 2000
---- ----
Cash and cash equivalents $ 12,836 $ 8,026
Accounts receivable--trade and other receivable, net 101,792 93,929
Inventories 82,773 85,778
Deferred taxes 7,306 6,087
Prepaid expenses 7,472 6,763
-------- --------
Total current assets 212,179 200,583
Property, plant and equipment, net 123,794 130,015
Intangible and other assets 90,020 95,940
-------- --------
Total assets 425,993 426,538
-------- --------
Accounts payable 44,927 42,140
Accrued expenses 42,465 38,924
Other current liabilities 10,979 7,922
-------- --------
Total current liabilities 98,371 88,986
Long-term debt 17,921 21,541
Other long-term liabilities 13,415 13,427
-------- --------
Total liabilities 129,707 123,954
-------- --------
Net assets of discontinued operations $296,286 $302,584
======== ========
28
New Accounting Pronouncements
Emerging Issues Task Force Issue No. 00-14, "Accounting for Certain Sales
Incentives" ("EITF Issue No. 00-14") outlines required accounting treatment for
certain sales incentives, including manufacturer's coupons. It requires
companies to record coupon expense as a reduction of sales, rather than
marketing expense. The consumer business currently records coupon expense as a
component of marketing expense. The Company is required to implement EITF Issue
No. 00-14 for the quarter beginning January 1, 2002. It will require the
consumer business to report coupon expense as a reduction of net sales. Coupon
expense in the consumer business approximates $6,000,000 per year based on
historical amounts, spread relatively evenly throughout the year.
Emerging Issues Task Force Issue No. 00-25, "Vendor Income Statement
Characterization of Consideration from a Vendor to a Retailer" ("EITF 00-25"),
outlines required accounting treatment of certain sales incentives, including
slotting or placement fees, cooperative advertising arrangements, buydowns and
other allowances. The consumer business currently records such costs as
marketing expenses. EITF 00-25 will require the consumer business to report the
paid consideration expense as a reduction of sales, rather than marketing
expense. The Company is required to implement EITF 00-25 for the quarter
beginning January 1, 2002. The Company has not yet determined the effect of
implementing the guidelines of EITF 00-25, but in any case, implementation will
not have an effect on net earnings.
16. SUPPLEMENTAL FINANCIAL INFORMATION
The following is presented in support of balance sheet captions:
MARCH 31
---------------------------
2001 2000
---- ----
(DOLLARS IN THOUSANDS)
Accrued expenses:
Salaries and wages $14,861 $18,615
Advertising and promotion 1,776 2,685
One-time charges 1,174 1,373
Retirement and related plans 6,287 11,766
Insurance 6,860 6,075
Pharmaceutical rebates 7,190 6,313
Product returns 3,845 3,247
Other 21,941 15,487
------- -------
$63,934 $65,561
======= =======
Other long-term liabilities:
Retirement plans $20,187 $19,001
One-time charges 12,104 8,700
Other 12,724 11,707
------- -------
$45,015 $39,408
======= =======
Income taxes paid, including discontinued operations, were $26,939,000,
$29,264,000 and $21,959,000 in 2001, 2000 and 1999, respectively. Interest paid,
including discontinued operations, was $4,173,000, $4,422,000 and $4,527,000 in
2001, 2000 and 1999, respectively.
Included in other expense (income), net is income of $140,000 in 2001,
$3,981,000 in 2000 and $6,782,000 in 1999 related to ASTA Medica's share of
joint venture operations. Also included in other expense (income), net is stock
award amortization of $9,115,000 in 2001, $5,729,000 in 2000 and $2,860,000 in
1999, and costs associated with the sharing of profits on a reformulated product
of $4,517,000 in 2001 and $550,000 in 2000.
29
17. QUARTERLY FINANCIAL DATA (UNAUDITED)
Quarterly net sales, gross margin, net earnings and earnings per share are set
forth in the following table (dollars in thousands, except per share amounts).
QUARTER ENDED
-----------------------------------------------------
2001 JUNE 30 SEPT. 30 DEC. 31 MARCH 31 TOTAL YEAR
- ---- -------- -------- -------- -------- --------
Net sales $ 66,822 $ 41,270 $ 70,453 $44,182 $222,727
Gross margin 53,490 30,921 54,995 32,549 171,955
Earnings (loss) from continuing
operations $ 4,040 $ (4,939) $ 2,928 $(2,363) $ (334)
Earnings from discontinued
operations 18,327 13,044 9,606 8,579 49,556
-------- -------- -------- -------- --------
Net earnings $ 22,367 $ 8,105 $ 12,534 $ 6,216 $ 49,222
======== ======== ======== ======== ========
Earnings (loss) per share from
continuing operations--basic $ .09 $ (.11) $ .06 $ (.05) $ (.01)
Earnings per share from
discontinued operations--basic .40 .29 .22 .19 1.10
-------- -------- -------- -------- --------
Earnings per share--basic $ .49 $ .18 $ .28 $ .14 $ 1.09
======== ======== ======== ======== ========
Earnings (loss) per share from
continuing operations--diluted $ .09 $ (.11) $ .06 $ (.05) $ (.01)
Earnings per share from
discontinued operations--diluted .39 .28 .20 .18 1.05
-------- -------- -------- -------- --------
Earnings per share--diluted $ .48 $ .17 $ .26 $ .13 $ 1.04
======== ======== ======== ======== ========
2000
- ----
Net sales $ 49,298 $ 44,765 $ 67,290 $46,513 $207,866
Gross margin 36,613 34,869 54,476 33,602 159,560
Earnings (loss) from continuing
operations $ (2,198) $ (2,435) $ 6,625 $ (633) $ 1,359
Earnings from discontinued
operations 15,359 11,835 7,331 7,448 41,973
-------- -------- -------- -------- --------
Net earnings $ 13,161 $ 9,400 $ 13,956 $ 6,815 $ 43,332
======== ======== ======== ======== ========
Earnings (loss) per share from
continuing operations--basic $ (.05) $ (.06) $ .15 $ (.01) $ .03
Earnings per share from
discontinued operations--basic .34 .27 .16 .16 .93
-------- -------- -------- -------- --------
Earnings per share--basic $ .29 $ .21 $ .31 $ .15 $ .96
======== ======== ======== ======== ========
Earnings (loss) per share from
continuing operations--diluted $ (.05) $ (.06) $ .15 $ (.01) $ .03
Earnings per share from
discontinued operations--diluted .34 .26 .15 .16 .91
-------- -------- -------- -------- --------
Earnings per share--diluted $ .29 $ .20 $ .30 $ .15 $ .94
======== ======== ======== ======== ========
30
31
K P M G
345 Park Avenue
New York, NY 10154
INDEPENDENT AUDITORS' REPORT
The Board of Directors and Stockholders
Carter-Wallace, Inc.:
We have audited the accompanying consolidated balance sheets of Carter-Wallace,
Inc. and subsidiaries as of March 31, 2001 and 2000, and the related
consolidated statements of earnings, retained earnings and comprehensive
earnings, and cash flows, for each of the years in the three-year period ended
March 31, 2001. These consolidated financial statements are the responsibility
of the Company's management. Our responsibility is to express an opinion on
these consolidated financial statements based on our audits.
We conducted our audits in accordance with auditing standards generally accepted
in the United States of America. Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the financial position of Carter-Wallace, Inc.
and subsidiaries as of March 31, 2001 and 2000, and the results of their
operations and their cash flows for each of the years in the three-year period
ended March 31, 2001, in conformity with accounting principles generally
accepted in the United States of America.
May 18, 2001
32
Carter-Wallace, Inc. and Subsidiaries
BOARD OF DIRECTORS
Henry H. Hoyt, Jr.
Chairman of the Board, Emeritus
Ralph Levine
Chairman of the Board and Chief Executive Officer
Paul A. Veteri
President and Chief Operating Officer
David M. Baldwin
Chairman, David M. Baldwin Realty Company, Inc.
Dr. Richard L. Cruess
Professor of Surgery, Center for Medical Education,
McGill University
Montreal, Quebec, Canada
Suzanne H. Garcia
Owner, La Tierra Beneficiaries (real estate development)
and Santa Fe Ranch
Scott C. Hoyt
Vice President, New Products
Carter Products Division of the Company
Herbert M. Rinaldi
Of Counsel
Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein
Donald J. Stack
Private Investor, Retired Vice President, Taxes of the Company
SCIENTIFIC ADVISORY BOARD
Joseph S. Harun, M.D., Chairman
Former Vice President, Medical and Scientific Affairs
Carter-Wallace, Inc.
Paul Calabresi, M.D.
Professor of Medicine and Chairman Emeritus,
Department of Medicine
Brown University
Director, Brown-Tufts Cancer Center
Providence, RI - Boston, MA
Robert E. Canfield, M.D.
Irving Professor of Medicine
Columbia University, College of Physicians and Surgeons
New York, NY
Barton F. Haynes, M.D.
Chairman, Department of Medicine
Duke University Medical Center
Durham, NC
Noel Rose, M.D., Ph.D.
Professor of Pathology, Molecular Microbiology and Immunology
Director of Immunology
Johns Hopkins University, Schools of Medicine and Public Health
Baltimore, MD
Morton K. Schwartz, Ph.D.
Chairman, Department of Clinical Laboratories
Memorial Sloan Kettering Cancer Center
New York, NY
EXECUTIVE OFFICERS
Ralph Levine
Chairman of the Board and Chief Executive Officer
Paul A. Veteri
President and Chief Operating Officer
T. Rosie Albright
Vice President, Consumer Products, U.S.
John Bridgen, Ph.D.
Vice President, Diagnostics, U.S.
James C. Costin, M.D.
Vice President, Medical and Scientific Affairs
Donald R. Daoust, Ph.D.
Vice President, Quality Control
Thomas G. Gerstmyer
Vice President, Pharmaceuticals, U.S.
Peter J. Griffin
Vice President, Finance and Controller
Adrian J. L. Huns
Vice President, International
Michael J. Kopec
Vice President, Manufacturing
Stephen R. Lang
Vice President, Secretary and General Counsel
Thomas B. Moorhead
Vice President, Human Resources
C. Richard Stafford
Vice President, Corporate Development
James L. Wagar
Vice President and Treasurer
Mark Wertlieb
Vice President, Taxes
DIVISIONAL MANAGEMENT
T. Rosie Albright, President, Carter Products
John Bridgen, Ph.D., President, Wampole Laboratories
Thomas G. Gerstmyer, President, Wallace Laboratories
Adrian J. L. Huns, President, International
Michael J. Kopec, President, Manufacturing
Thomas M. McShane, President, Lambert Kay
PRINCIPAL SUBSIDIARIES
Howard E. Cocker, Managing Director, Carter-Wallace Limited (United Kingdom)
Francois Depoil, President, Laboratoires Fumouze S. A. (France)
Gregory J. Drohan, President, Carter-Horner Inc. (Canada)
Alan W. Nash, Managing Director, Carter-Wallace (Australia)
Pty. Limited
Jordi Pruja, Managing Director, Icart S.A. (Spain)
Stephen W. Riley, President, Carter Wallace, S. A. (Mexico)
Lino Santambrogio, Managing Director, S.p.A. Italiana
Laboratori Bouty (Italy)
33
34 Printed in U.S.A.
CARTER-WALLACE, INC.
1345 Avenue of the Americas
New York, NY 10105